Pulmonary hypertension: A correct diagnosis for a suitable therapy in scleroderma patients

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 182-189

  Giordano, Nicola ^a   Montella, Antonio ^a   Corallo, Claudio ^a   Ruocco, Gaetano ^a   Chirico, Chiara ^a   Palazzuoli, Alberto ^a   Nuti, Ranuccio ^a   Pecetti, Gianluca ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b Actelion Pharmaceuticals Italia   (Italy)

Author keywords

Pulmonary arterial hypertension; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

AMBRISENTAN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; RIOCIGUAT; SILDENAFIL; TADALAFIL; TREPROSTINIL; ANTIHYPERTENSIVE AGENT;

DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; ANIMAL; ARTERIAL PRESSURE; COMPLICATION; DRUG EFFECTS; HYPERTENSION, PULMONARY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY ARTERY; RISK FACTOR; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; HUMANS; HYPERTENSION, PULMONARY; PREDICTIVE VALUE OF TESTS; PULMONARY ARTERY; RISK FACTORS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84946230796     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. FISHMAN AP: Clinical classification of pulmonary hypertension. Clin Chest Med 2001; 22: 385-91.
2. TUDER RM, ARCHER SL, DORFMüLLER P et al.: Relevant issue in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D4-12.
3. GALIE N, SIMONNEAU G: The Fifth World Symposium on Pulmonary Hypertension. J Am Coll Cardiol 2013; 62: D1-3.
4. SIMONNEAU G, GATZOULIS MA, ADATIA I et al.: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34-41.
5. McLAUGHLIN VV, ARCHER SL, BADESCH DB et al.: American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-619.
6. MATHAI SC, HASSOUN PM: Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin 2012; 8: 413-25.
7. COGHLAN JG, DENTON CP, GRüNIG E et al.: DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340-9.
8. IUDICI M, CODULLO V, GIUGGIOLI D et al.: Pulmonary hypertension in systemic sclerosis: prevalence, incidence and predictive factors in a large multicentric Italian cohort. Clin Exp Rheumatol 2013; 31: 31-6.
9. BAE S, SAGGAR R, BOLSTER MB et al.: Baseline characteristics and followup in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis 2012; 71: 1335-42.
10. NINABER MK, HAMERSMA WB, SCHOUFFOER AA et al.: Detection of pulmonary vasculopathy by novel analysis of oxygen uptake in patients with systemic sclerosis: association with pulmonary arterial pressures. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S60-7.
11. van den HOOGEN F, KHANNA D, FRANSEN J et al.: 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
12. ARCHER SL, WEIR EK, WILKINS MR: Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010; 121: 2045-66.
13. SHETTY N, DERK CT: Endothelin receptor antagonists as disease modifiers in systemic sclerosis. Inflamm Allergy Drug Targets 2011; 10: 19-26.
14. GIORDANO N, PAPAKOSTAS P, PECETTI G, NUTI R: Cytokine modulation by endothelin-1 and possible therapeutic implications in systemic sclerosis. J Biol Regul Homeost Agents 2011; 25: 487-92.
15. SHI-WEN X, RODRíGUEZ-PASCUAL F, LAMAS S et al.: Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol 2006; 26: 5518-27.
16. RONDELET B, KERBAUL F, MOTTE S et al.: Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 2003; 107: 1329-35.
17. HUMBERT M, SITBON O, CHAOUAT A et al.: Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-63.
18. CHAMPION HC, MICHELAKIS ED, HASSOUN PM: Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 2009; 120: 992-1007.
19. BENZA RL, MILLER DP, GOMBERG-MAITLAND M et al.: Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-72.
20. RUDSKI LG, LAI WW, AFILALO J et al.: Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23: 685-713.
21. HACHULLA E, GRESSIN V, GUILLEVIN L et al.: Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-800.
22. MUKERJEE D, St GEORGE D, COLEIRO B et al.: Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-93.
23. TYNDALL AJ, BANNERT B, VONK M et al.: Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
24. HUMBERT M, YAICI A, de GROOTE P et al.: Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long term survival. Arthritis Rheum 2011; 63: 3522-30.
25. HACHULLA E, LAUNAY D, MOUTHON L et al.: French PAH-SSc Network. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 2009; 136: 1211-9.
26. NAEIJE R, VACHIERY JL, YERLY P, VANDERPOOL R: The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013; 41: 217-23.
27. MAGNE J, LANCELLOTTI P, PIéRARD LA: Exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation. Circulation 2010; 122: 33-41.
28. TEDFORD RJ, HASSOUN PM, MATHAI SC et al.: Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation 2012; 125: 289-97.
29. OUDIZ RJ: Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 2007; 28: 233-41.
30. DELGADO JF, CONDE E, SáNCHEZ V et al.: Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005; 7: 1011-6.
31. de GROOTE P, GRESSIN V, HACHULLA E et al.: ItinerAIR-Scleroderma Investigators. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 31-6.
32. BURSI F, McNALLAN SM, REDFIELD MM et al.: Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol 2012; 59: 222-31.
33. SEEGER W, ADIR Y, BARBERà JA et al.: Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62: D109-16.
34. McGOON MD, BENZA RL, ESCRIBANO-SUBIAS P et al.: Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62: D51-9.
35. POPE JE, LEE P, BARON M et al.: Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005; 32: 1273-8.
36. ZANGIABADI A, de PASQUALE CG, SAJKOV D: Pulmonary Hypertension and Right Heart Dysfunction in Chronic Lung Disease. Biomed Res Int 2014; 2014: 739674.
37. HOEPER MM, BOGAARD HJ, CONDLIFFE R et al.: Definition and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D42-50.
38. KIM NH, DELCROIX M, JENKINS DP et al.: Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62: D92-9.
39. VACHIéRY JL, COGHLAN G: Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2009; 18: 162-9.
40. SCHWAIGER JP, KHANNA D, GERRY COGHLAN J: Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. Eur Respir Rev 2013; 22: 515-25.
41. GALIE N, HOEPER MM, HUMBERT M et al.: ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-537.
42. FISCHER A, SWIGRIS JJ, BOLSTER MB et al.: Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S109-14.
43. KHANNA D, GLADUE H, CHANNICK R et al.: Recommendation for screening and detection of connective tissue disease-associate pulmonary arterial hypertension. Arthritis & Rheumatism 2013; 65: 3194-201.
44. GALIE N, CORRIS PA, FROST A et al.: Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: D60-71.
45. GIAID A, SALEH D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-21.
46. GHOFRANI HA, GALIE N, GRIMMINGER F et al.: PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-40.
47. WHARTON J, STRANGE JW, MØLLER GM et al.: Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172: 105-13.
48. TANTINI B, MANES A, FIUMANA E et al.: Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005; 100: 131-8.
49. GHOFRANI HA, VOSWINCKEL R, REICHENBERGER F et al.: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004; 44: 1488-96.
50. SIMONNEAU G, RUBIN LJ, GALIE N et al.: PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Intern Med 2008; 149: 521-30.
51. VACHIERY JL, HUEZ S, GILLIES H et al.: Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br J Clin Pharmacol 2011; 71: 289-92.
52. GALIE N, BRUNDAGE BH, GHOFRANI HA et al.: Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-903.
53. JONES DA, BENJAMIN CW, LINSEMAN DA: Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995; 48: 890-6.
54. CHRISTMAN BW, MCPHERSON CD, NEWMAN JH et al.: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-5.
55. GALIE N, MANES A, BRANZI A: Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003; 2: 123-37.
56. RUBIN LJ, MENDOZA J, HOOD M et al.: Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485-91.
57. BARST RJ, RUBIN LJ, LONG WA et al.: Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.
58. BADESCH DB, TAPSON VF, McGOON MD et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425-34.
59. SIMONNEAU G, BARST RJ, GALIE N et al.: Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-4.
60. McLAUGHLIN VV, BENZA RL, RUBIN LJ et al.: Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915-22.
61. HIREMATH J, THANIKACHALAM S, PARIKH K et al.: TRUST Study Group. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 2010; 29: 137-49.
62. McLAUGHLIN VV, OUDIZ RJ, FROST A et al.: Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-63.
63. HOEPER MM, LEUCHTE H, HALANK M et al.: Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 4: 691-4.
64. OLSCHEWSKI H: Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev 2009; 18: 29-34.
65. A. GIAID, M. YANAGISAWA, D. LANGLEBEN et al.: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-9.
66. STEWART DJ, LEVY RD, CERNACEK P, LANGLEBEN D: Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464-9.
67. GALIE N, MANES A, BRANZI A: The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-37.
68. GALIé N, BADESCH D, OUDIZ R et al.: Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-35.
69. GALIE N, OLSCHEWSKI H, OUDIZ RJ et al.: Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-9.
70. CHANNICK RN, SIMONNEAU G, SITBON O et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-23.
71. RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
72. HUMBERT M, BARST RJ, ROBBINS IM et al.: Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-9.
73. GALIE N, RUBIN LJ, HOEPER M et al.: Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-100.
74. SAVARESE G, PAOLILLO S, COSTANZO P et al.: Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension?: A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192-201.
75. McLAUGHLIN VV, GAINE SP, HOWARD LS et al.: Treatments goals of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D73-81.
76. PULIDO T, ADZERIKHO I, CHANNICK RN et al.: SERAPHIN Investigators. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 809-18.
77. VONK-NOORDEGRAAF A, HADDAD F, CHIN KM et al.: Right heart adaptation to pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: D22-33.
78. LAUNAY D, SITBON O, HACHULLA E et al.: Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013; 72: 1940-6.
79. VACHIERY JL, ADIR Y, BARBERà JA et al.: Pulmonary Hypertension due to left heart disease. JACC 2013; 62: 100-8.